In preclinical studies, C-REV replicated effectively within tumors and induced an antitumor immune response, as evidenced by an increase in the numbers of activated CD4+, CD8+ T, and NK cells in tumor tissues, leading to prolonged survival and a significant reduction in tumor growth [102]. Here, CD4 is linked to neoplasm.